Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MEDI4736 combinations in metastatic renal cell carcinoma

Trial Profile

MEDI4736 combinations in metastatic renal cell carcinoma

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 08 Dec 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Durvalumab (Primary) ; Savolitinib (Primary) ; Tremelimumab (Primary)
  • Indications Renal cell carcinoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms CALYPSO
  • Most Recent Events

    • 24 Oct 2023 Results of updated 24-month efficacy analysis presented at the 48th European Society for Medical Oncology Congress.
    • 18 Feb 2023 Results assessing relationship between MET, PD-L1 and TMB in these tumors and the relevance of other biomarkers including PIK3CA, PTEN and KRAS presented at the 2023 Genitourinary Cancers Symposium
    • 12 Feb 2023 Results (n=41) investigating the Safety and Efficacy of Savolitinib and Durvalumab in Metastatic Papillary Renal Cancer , published in the Journal of Clinical Oncology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top